Stockscreener 앱 받기
7.87
3.44%
-0.28
시간 외 거래:
7.90
0.03
+0.38%
전일 마감가:
$8.15
열려 있는:
$8.22
하루 거래량:
115.69K
Relative Volume:
1.17
시가총액:
$135.83M
수익:
-
순이익/손실:
$-33.82M
주가수익비율:
-0.3076
EPS:
-25.5891
순현금흐름:
$-66.04M
1주 성능:
-2.24%
1개월 성능:
-9.75%
6개월 성능:
-1.01%
1년 성능:
+52.82%
1일 변동 폭
$7.725
$8.25
1주일 범위
$7.725
$8.78
52주 변동 폭
$4.60
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
ELTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
7.87 | 140.66M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - The Manila Times
Understanding Momentum Shifts in (ELTX) - news.stocktradersdaily.com
Elicio Therapeutics (ELTX) upgraded to buy: Here's why - MSN
Elicio’s cancer vaccine triggers broad anti-tumor immunity - Rare Cancer News
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why - sharewise.com
Elicio reports antigen spreading in 87% of evaluated cancer patients By Investing.com - Investing.com Australia
Elicio reports antigen spreading in 87% of evaluated cancer patients - Investing.com India
Elicio Therapeutics (Nasdaq: ELTX) shows T cell antigen spreading in 13 of 15 Phase 2 patients - Stock Titan
Pancreatic Ductal Adenocarcinoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Elicio Therapeutics, Cend Therapeutics, Silenseed, Amplia - Barchart.com
How Elicio Therapeutics Inc. (9HA) stock reacts to stronger dollarQuarterly Market Summary & Safe Capital Allocation Plans - Newser
How Elicio Therapeutics Inc. (9HA) stock reacts to new regulations2025 Winners & Losers & Long-Term Growth Plans - Newser
Will Elicio Therapeutics Inc. (9HA) stock benefit from mergersTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Avoiding Lag: Real-Time Signals in (ELTX) Movement - news.stocktradersdaily.com
Can Elicio Therapeutics Inc. stock deliver surprise earnings beat2025 Volatility Report & Real-Time Buy Zone Alerts - Newser
Can Elicio Therapeutics Inc. (9HA) stock sustain margin levelsAnalyst Downgrade & Safe Capital Growth Plans - Newser
Will Elicio Therapeutics Inc. stock benefit from AI adoptionWeekly Stock Recap & Weekly Stock Performance Updates - Newser
How Elicio Therapeutics Inc. (9HA) stock trades in high volatilityWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Is Elicio Therapeutics Inc. (9HA) stock undervalued historicallyTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Will Elicio Therapeutics Inc. (9HA) stock split increase liquidity2025 Earnings Surprises & Fast Moving Market Watchlists - Newser
How Elicio Therapeutics Inc. (9HA) stock compares with top peers - Newser
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - MSN
Discipline and Rules-Based Execution in ELTX Response - news.stocktradersdaily.com
Can Elicio Therapeutics Inc. (9HA) stock sustain breakout momentumQuarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Is Elicio Therapeutics Inc. stock a smart buy before Fed meeting2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Why Elicio Therapeutics Inc. (9HA) stock remains stableProfit Target & Consistent Return Investment Signals - newser.com
How Elicio Therapeutics Inc. stock performs in weak economyJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Can Elicio Therapeutics Inc. stock maintain operating marginsQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
Retail investors are Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) biggest owners and were hit after market cap dropped US$8.5m - simplywall.st
How Elicio Therapeutics Inc. (9HA) stock performs during market turbulenceJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - newser.com
Can Elicio Therapeutics Inc. stock outperform in 2025 bull market2025 Biggest Moves & Free High Accuracy Swing Entry Alerts - newser.com
How high can Elicio Therapeutics Inc. stock goJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Elicio Therapeutics appoints Marc Wolfgang as chief technology officer By Investing.com - Investing.com Nigeria
Elicio Therapeutics Inc. stock trendline breakdownTrade Entry Summary & Low Volatility Stock Suggestions - newser.com
What earnings revisions data tells us about Elicio Therapeutics Inc.Trade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer - MarketScreener
Elicio Therapeutics appoints Marc Wolfgang as chief technology officer - Investing.com
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):